[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.62.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 26, 1949

AUREOMYCIN IN TREATMENT OF EXPERIMENTAL AND HUMAN TULAREMIA

Author Affiliations

Baltimore

From the Department of Medicine, School of Medicine, University of Maryland. Associate Professor of Medicine (Dr. Woodward), Resident in Medicine (Dr. Raby), Assistant Resident in Medicine (Dr. Eppes), Assistant in Medicine (Dr. Holbrook) and Intern in Medicine (Dr. Hightower).

JAMA. 1949;139(13):830-832. doi:10.1001/jama.1949.02900300016005
Abstract

The new antibiotic, aureomycin, first described by Duggar,1 has been shown to exert specific effect when administered to patients suffering with diseases caused by gram-negative2 and certain gram-positive organisms.2b Detailed reports of its usefulness in rickettsial infections have now been recorded, and aureomycin perhaps exerts its greatest influence in this group of diseases.3 Favorable results from its employment in lymphogranuloma inguinale have been published.4 No toxic effects other than nausea and occasional diarrhea attributable to the drug have been observed in our experience or in the patients who have been treated with this agent and reported in the medical literature.

We have been interested in the chemotherapy of tularemia since 1947, when para-aminobenzoic acid (PABA) was observed by us to exert slight benefit in mice experimentally infected with Bacterium tularense. This effect, however, did not in any way approach that achieved with streptomycin, but in

First Page Preview View Large
First page PDF preview
First page PDF preview
×